Articles related to PROSTATE CANCER

At a median follow-up of 24 months following initial PSMA PET scans, 73 of the 226 patients studied had clinical recurrence (CR). The 3-year CR-free rates in the 109-person metastasis-directed therapy (MDT) group were 51% and 28% in the no MDT group (117), respectively. Men who did not receive MDT had a significantly higher rate of distant metastases at CR than those who did (86% vs. 77%). The proportion of distant metastases was significantly lower in the MDT group (67% vs. 76%).

The ideal regimen recommended by the guidelines for those with metastatic hormone-sensitive prostate cancer (mHSPC) is darolutamide, ADT, and docetaxel. The combination of ADT and androgen receptor pathway inhibition, which was the norm at the start of the ARASENS trial, has changed the therapeutic landscape for mHSPC; this analysis offers crucial information for choosing the right course of action for particular patients.

In the United States, prostate cancer is the second most prevalent type of cancer in men, and it is the main cause of death for men ages 75 and older. Despite the slow progression of the disease, it is critical for men to recognize potential symptoms and seek medical attention before the cancer progresses.

The purpose of this study was to assess the relationship between the RTOG clinical target volumes (CTVs) and PSMA PET-defined recurrence topography, as well as to analyze the patterns of prostate bed (PB) recurrence in prostate cancer patients who had PSA persistence (BCP) or biochemical recurrence (BCR) following radical prostatectomy.

A group of UK researchers has created a novel prostate cancer (PaC) screening test (EpiSwitch) that, when combined with the prostate specific antigen (PSA) test, has a high degree of accuracy for detecting the cancer. The test is based on measurement of five chromosome conformations that were first discovered in association with advanced PaC. The EpiSwitch test has a high positive predictive value for the diagnosis of PaC (92%) and a high negative predictive value (94%) when used in conjunction with the PSA level as a continuous variable, according to the researchers. The study’s authors advocated for additional research to investigate the test’s efficacy in larger patient samples, even though it was based on a scant number of patient samples.

The first standalone AI-based cancer diagnostics product of its kind to receive Vitro Diagnostic Medical Devices Regulation (IVDR) certification is Galen Prostate. Ibex intends to transition more goods, such as its Galen Breast and Galen Gastric solutions, under the IVDR accreditation during 2023.